Edwards lands four-year $500 million revolving credit facility | Funding Roundup

Edwards Lifesciences Corp. (NYSE:EW) landed a new four-year $500 million credit facility after canceling a prior one a couple months early.

The old facility was a five-year deal, also for $500 million, that was scheduled to mature September 29, 2011.

Under the new agreement, Edwards, which ranked 46th on the MassDevice Big 100 list of the world’s largest medical device companies, is eligible to increase its facility up to another $250 million, subject to certain terms and conditions.

Here’s a roundup of other dealflow and investment news:

• Knome raises $5 million for gene sequencing
  Cambridge, Mass.-based Knome Inc. raised $5 million of a $20 million equity funding round that began mid-July. The $5 million came from one unnamed investor, filings show.
  Read more
• Cardia touts closes $2 million round
  Minnesota-based Cardia Inc., maker of cardiac implants for treatment of congenital heart defects, closed a $2 million funding round spread across 24 investors.
  Read more
• NeoChord pulls in nearly half of a $11 million round
  Minnesota-based biotech firm NeoChord Inc. raised just over $5 million of a $11 million series B preferred stock and warrant round, gathered from 44 investors. NeoChord makes a minimally invasive implant for patients with ruptured or elongated mitral valves.
  Read more
• Restoration Robotics touts $41 million for hair restoration
  Restoration Robotics Inc. landed $41 million through a series C financing round. Investment in the physician-controlled, computer-aided hair restoration robotics company was led by Clarus Ventures, and joined by Sutter Hill Ventures, Alloy Ventures and Interwest Partners.
  Read more
• Vessix Vascular closes a $23 million round
  Laguna Hills, Calif.-based radiofrequency catheter maker Vessix Vascular Inc. closed a $23 million series B preferred stock financing round led by Edmond de Rothschild Investment Partners. The company plans to use the funds as working capital to accelerate development initiatives and to fund clinical trials to expand clinical indications for its RF balloon catheter technology.
  Read more
• Abaxis repurchases stock
  Abaxis Inc.’s (NSDQ:ABAX) board of directors approved a $40 million common stock repurchase program, to be made from time to time on the open market.
  Read more
• Acutus Medical wins $1 million from private investors
  San Diego, Calif.-based Acutus Medical Inc. landed a $1 million investment from private investors, including Index Ventures. The company develops electrophysiological mapping technology for treatment of cardiac arrhythmias.
  Read more